15353-j-veluchamy

6 General discussion and Future Prospects | 159 31. Sahm C, Schonfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer immunology, immunotherapy : CII (2012) 61 (9):1451-61. Epub 2012/02/09. doi: 10.1007/ s00262-012-1212-x. PubMed PMID: 22310931. 32. Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget (2016) 7 (19):27764-77. doi: 10.18632/oncotarget.8526. PubMed PMID: PMC5053686. 33. Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia (2014) 28 (4):917-27. Epub 2013/09/27. doi: 10.1038/leu.2013.279. PubMed PMID: 24067492; PubMed Central PMCID: PMCPMC3967004. 34. Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular oncology (2014) 8 (2):297-310. Epub 2014/01/07. doi: 10.1016/j.molonc.2013.12.001. PubMed PMID: 24388357. 35. Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, et al. Retargeting NK- 92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology (2013) 2 (10):e26527. Epub 2014/01/10. doi: 10.4161/onci.26527. PubMed PMID: 24404423; PubMed Central PMCID: PMCPMC3881109. 36. Klingemann H, Boissel L, Toneguzzo F. Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells. Front Immunol (2016) 7 :91. Epub 2016/03/26. doi: 10.3389/ fimmu.2016.00091. PubMed PMID: 27014270; PubMed Central PMCID: PMCPMC4789404. 37. Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuejoul S. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. Annales de pathologie (2016) 36 (1):94-102. Epub 2016/01/19. doi: 10.1016/j.annpat.2015.11.004. PubMed PMID: 26778219. 38. Borcherding N, Kusner D, Liu G-H, Zhang W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein & Cell (2014) 5 (7):496-502. doi: 10.1007/s13238-014-0059-7. PubMed PMID: PMC4085287. 39. Chang Y-H, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells. Cancer Research (2013) 73 (6):1777-86. doi: 10.1158/0008-5472.can-12-3558. 40. Kamiya T, Chang YH, Campana D. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma. Cancer immunology research (2016) 4 (7):574-81. Epub 2016/05/20. doi: 10.1158/2326-6066.cir-15-0229. PubMed PMID: 27197065. 41. Torikai H, Mi T, Gragert L, Maiers M, Najjar A, Ang S, et al. Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Scientific reports (2016) 6 :21757. doi: 10.1038/srep21757 http://www.nature.com/articles/srep21757#supplementary -information.